Clinical trials: Glaucoma Open-angle
Open Angle Glaucoma, Ocular Hypertension
DE-111 Against Timolol Ophthalmic Solution 0.5%
DE-111 ophthalmic solution will be evaluated for superiority in comparison with Timolol ophthalmic solution 0.5%, in IOP(intraocular pressure ) -lowering effect in primary open-angle glaucoma or ocular hypertension patients, in a…
- Trial name
- NCT01342094
- Testing
- DE-111 ophthalmic solution, Timolol ophthalmic solution 0.5%
- Where
- Japan
- Volunteers
- 166 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Primary Open-angle Glaucoma, Ocular Hypertension
Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of the study is to compare the efficacy and safety of Timolol 0.5% solution to Brinzolamide 1% each given twice daily when added to Travoprost 0.004% given each evening.
- Conditions
- Primary Open-angle Glaucoma, Ocular Hypertension, Pigment Dispersion Glaucoma
- Trial name
- NCT00372827
- Testing
- Brinzolamide 1% added to Travoprost 0.004%
- Where
- Germany
- Volunteers
- 245 people
- Sponsor
- Alcon Research
Open Angle Glaucoma, Ocular Hypertension
Efficacy Study of Travoprost APS Versus TRAVATAN
A Multi-Center Double-masked Study of the Safety and Efficacy of Travoprost APS Compared to TRAVATAN in Patients with Open-angle Glaucoma or Ocular Hypertension
- Trial name
- NCT00848536
- Testing
- Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution, Travoprost 0.004% (BAK-preserved) Eye Drops, Solution
- Volunteers
- 371 people
- Sponsor
- Alcon Research
Open-angle Glaucoma, Ocular Hypertension
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00287521
- Testing
- AL-37807 Ophthalmic Suspension, 1.0%, Latanoprost, 0.005% (Xalatan), AL-37807 Vehicle
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Alcon Research
Glaucoma
AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure
The purpose of this study was to assess the safety and efficacy of switching to Azarga from prior pharmacotherapy in patients with open-angle glaucoma.
- Trial name
- NCT01484951
- Testing
- Brinzolamide 1% and timolol 0.5% fixed combination eye drops
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Alcon Research
Open Angle Glaucoma, Ocular Hypertension
Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma
The objectives of this study are: To evaluate the efficacy of Phentolamine Mesylate to lower intra-ocular pressure (IOP) in the treatment of Open-Angle Glaucoma (OAG) and Ocular Hypertension (OHT).
- Trial name
- NCT03960866
- Testing
- Phentolamine Mesylate Ophthalmic Solution 1%
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Opus Genetics, Inc
Primary Open Angle Glaucoma or Ocular Hypertension
A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study
The purposes of this study are to investigate the effect of intraocular pressure lowering efficacy and safety of DE-117 ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension who are…
- Trial name
- NCT02822742
- Testing
- DE-117 ophthalmic solution, Latanoprost ophthalmic solution 0.005%
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
- Trial name
- NCT01632423
- Testing
- bimatoprost 0.01%
- Where
- Germany
- Volunteers
- 10,337 people
- Sponsor
- Allergan
Open Angle Glaucoma
Study of OMNI System in OAG (GEMINI)
This study will prospectively assess the clinical effect of ab-interno transluminal viscoelastic delivery and trabeculotomy performed using the OMNI Surgical System in combination with Cataract Extraction on intraocular pressure…
- Trial name
- NCT03861169
- Testing
- Transluminal viscoelastic delivery and trabeculotomy
- Where
- 15 sites in United States
- Volunteers
- 209 people
- Sponsor
- Sight Sciences, Inc.
Open-Angle Glaucoma, Ocular Hypertension
A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to determine whether AL-37807 is safe and effective in treating patients with open-angle glaucoma or ocular hypertension
- Trial name
- NCT00372931
- Testing
- AL-37807
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Alcon Research
Glaucoma
Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol
The purpose of this study was to assess the safety and intraocular pressure (IOP)-lowering efficacy of changing to DuoTrav® from prior timolol 0.5% monotherapy in participants with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01336569
- Testing
- Travoprost 0.004%/timolol maleate 0.5% fixed combination
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma
A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma
A Randomized Clinical Trial of Ab Interno Canaloplasty and Trabeculotomy with the OMNI® Surgical System Compared to Standard Medical Treatment as a Standalone Procedure in Patients with Primary Open Angle Glaucoma (EVOLVE)
- Trial name
- EVOLVE (NCT06407973)
- Testing
- OMNI Surgical System, Latanoprost plus adjunctive glaucoma medication
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Sight Sciences, Inc.
Open-Angle Glaucoma, Ocular Hypertension
A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension
The primary objective of this study is to compare the safety and efficacy of Brimonidine Tartrate Ophthalmic Solution, 0.15% in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00061529
- Testing
- Brimonidine Tartrate Ophthalmic Solution
- Where
- United States
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Glaucoma Eye
MINIject Glaucoma Implant in European Patients
The study will evaluate the efficacy and safety of the MINIject glaucoma implant and Intraocular Pressure (IOP) lowering effects with or without glaucoma medications. The procedure will be a stand-alone surgery.
- Conditions
- Glaucoma, Open-Angle, Glaucoma Eye, Intraocular Pressure
- Trial name
- STAR-II (NCT03624361)
- Testing
- Glaucoma device implantation in a stand-alone procedure
- Where
- 8 sites in France, Germany and 1 more
- Volunteers
- 29 people
- Sponsor
- iSTAR Medical
Glaucoma, Primary Open Angle, Ocular Hypertension
A Study of Bimatoprost 0.01% in the Clinical Setting
This is a study of bimatoprost 0.01% (LUMIGAN® 0.01%) in subjects with primary open-angle glaucoma (POAG) or ocular hypertension (OH) who require further treatment for elevated intraocular pressure (IOP).
- Trial name
- APPEAL-Taiwan (NCT01814761)
- Testing
- Bimatoprost 0.01%
- Where
- Taiwan
- Volunteers
- 312 people
- Sponsor
- Allergan
Ocular Hypertension, Glaucoma, Open-Angle
Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.
The primary purpose is to compare the intraocular pressure reducing effect of Xalatan with that of usual care over 36 months. Safety and health care utilization will be evaluated.
- Trial name
- NCT00140062
- Testing
- latanoprost 0.005% (Xalatan)
- Where
- 27 sites in Finland, Sweden
- Volunteers
- 329 people
- Sponsor
- Pfizer
Glaucoma
Open Label Extension of LipoLat-CS202
This is an open-label, observational extension of patients who received POLAT-001 in LipoLat-CS202.
- Trial name
- NCT02599688
- Testing
- Observation only
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Peregrine Ophthalmic